摘要
目的:观察蔗糖铁注射液治疗血液透析患者肾性贫血的疗效与安全性。方法:选择20例规律血液透析的慢性肾功能衰竭中度贫血患者,给予每周2次、每次100 mg、总剂量1000 mg的静脉蔗糖铁注射液治疗。在患者入组前及入组的第2、4、6、8周末测血常规、血清铁蛋白(SF),入组前和入组后8周时测C反应蛋白(CRP)、甲状旁腺激素(PTH)、谷丙转氨酶(ALT)与谷草转氨酶(AST)水平,并在8周末计算贫血治疗的有效率。结果:静脉输注蔗糖铁治疗后患者的血红蛋白(Hgb)、红细胞压积(HCT)、血清铁蛋白均明显升高,而CRP、PTH、ALT、AST均无明显变化。结论:蔗糖铁注射液治疗血液透析患者肾性贫血是有效且安全的。
Objective： To observe the efficacy and safety of intravenous iron sucrose in treating anemic hemodialysis patients.Method： Twenty maintenance anemic hemodialysis patients were given intravenous iron sucrose therapy.100 milligram intravenous iron sucrose was given twice per week to every patients,the period of treatment was 5 weeks and the total dose of iron sucrose was 1000 milligram.The blood routine and serume ferritin（SF）were tested at the end of 0,2,6,8 week,C reactive protein（CRP）,ParathyroidHormone（PTH）、alanine aminotransferase（ALT） and aspartate aminotransferase（AST） were tested at the end of 0 and 8 weeks.The effective rate of anemia treatment was calculated at the end of 8 week.Result： Intravenous iron sucrose therapy significantly increased anemic hemodialysis patients＇ hemoglobulin（Hb） and hemotocrit（HCT）.At the same time,intravenous iron sucrose therapy did not influence CRP、PTH、ALT or AST.Conclusion： Intravenous iron sucrose is effective and safe in treating anemic patients during hemodialysis.
出处
《河北医学》
CAS
2011年第12期1567-1570,共4页
Hebei Medicine
